European Medicines Agency – Yescarta receives positive CHMP opinion for extension of indication (Cell and Gene Therapy Catapult – Regulatory Round-up – April 2022)
The CHMP adopted a new indication for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.
See all of Catapult’s Regulatory Round-up for April 2022 here. Published on the 29th of April 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (3 août 2022). European Medicines Agency – Yescarta receives positive CHMP opinion for extension of indication (Cell and Gene Therapy Catapult – Regulatory Round-up – April 2022). ELSIBI. Consulté le 18 février 2026 à l’adresse https://doi.org/10.58079/o61t





